This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sansone-Parsons, A.
Right arrow Articles by Stoltz, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sansone-Parsons, A.
Right arrow Articles by Stoltz, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2007, p. 495-502, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00472-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers{triangledown}

Angela Sansone-Parsons,1* Gopal Krishna,1 Jason Simon,1 Peter Soni,1 B. Kantesaria,1 Jerry Herron,2 and Randall Stoltz3

Schering-Plough Research Institute, Kenilworth, New Jersey,1 Research Solutions, Little Rock, Arkansas,2 Covance GFI Research, Evansville, Indiana3

Received 17 April 2006/ Returned for modification 30 August 2006/ Accepted 31 October 2006

Posaconazole is a triazole antifungal for prophylaxis of invasive fungal infection and treatment of oropharyngeal candidiasis. We evaluated the effects of gender, age, and race/ethnicity (black or white) on the steady-state pharmacokinetics of posaconazole in two studies on healthy adult subjects (≥18 years of age). Additionally, we explored the effect of P-glycoprotein expression and MDR1 genotype on posaconazole pharmacokinetics in black and white subjects. Age, gender, and race/ethnicity had no clinically relevant effects on posaconazole pharmacokinetics. No association was observed between any MDR1 single-nucleotide polymorphism and the area under the concentration-time curve for posaconazole. Posaconazole was safe and well tolerated regardless of age, gender, or race/ethnicity. In conclusion, age, gender, and race/ethnicity have no clinically relevant effects on the steady-state pharmacokinetics of posaconazole in healthy adults; therefore, dosage adjustments based on these covariates are unnecessary.

* Corresponding author. Mailing address: Schering-Plough Research Institute, K15-4-4455, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Phone: (908) 740-4093. Fax: (908) 740-2169. E-mail: angela.sansone{at}spcorp.com.

{triangledown} Published ahead of print on 13 November 2006.

Antimicrobial Agents and Chemotherapy, February 2007, p. 495-502, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00472-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dodds Ashley, E. S., Varkey, J. B., Krishna, G., Vickery, D., Ma, L., Yu, X., Malavade, D., Goodwin, M., Perfect, J. R., Power, E. (2009). Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 2960-2964 [Abstract] [Full Text]  
  • Krishna, G., Moton, A., Ma, L., Medlock, M. M., McLeod, J. (2009). Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 958-966 [Abstract] [Full Text]  
  • Rachwalski, E. J, Wieczorkiewicz, J. T, Scheetz, M. H (2008). Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. The Annals of Pharmacotherapy 42: 1429-1438 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»